comprehensive -WSS

comprehensive

author：entertainment 2025-09-27 15:00:07 - browse：1918

Sanofi CEO Paul Hudson Courtesy Sanofi

NEW YORK — The top executives at French drug giant Sanofi on Wednesday defended their decision to reduce earnings forecasts for 2024 in order to fund more research studies of new medicines they say could one day generate billions of dollars in annual sales.

CEO Paul Hudson and Houman Ashrafian, Sanofi’s new head of R&D, made their remarks in an exclusive interview with STAT ahead of a full-day meeting with analysts here. When the cuts to earnings were first announced Oct. 27, along with a plan to spin off the company’s consumer products division, shares dove 18% and have yet to fully recover. The share price is down 5% since the beginning of 2023.

“I’ve been waiting four years for a situation where we could put [out] the pipeline, as impressive as it is, and declare that we’re going to be the world’s leading immunology company,” said Hudson, who took over as CEO in 2019. “So it’s quite an important moment for us. And it’s an important moment to declare that we’re back in science, because I could argue that we haven’t been where we needed to be.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： The (many) problems with a new study criticizing cancer screening

entertainment

WSS

STAT Summit: Michael J. Fox on progress in Parkinson's research

Studies point to risks of excluding people with obesity from drug trials

2023 STAT Wunderkinds: get to know the winners

UnitedHealth’s board chair also owns a personal investment firm

Seth Rogen and Lauren Miller Rogen on Alzheimer's caregiving

ALS advocates say criticism of new drugs misses bigger picture

knowledge

comprehensive

knowledge

At least 13 dead in Texas as scorching temps continue

Advances in CAR

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

ALS advocates say criticism of new drugs misses bigger picture

After affirmative action ruling, medical educators look to 'holistic review'

Crinetics acromegaly drug succeeds in late

Walensky prepares to leave CDC — and Congress — behind

Snackable artificial intelligence, expert AI, and the pharma industry

Medical records are filled with copy

The EU Joint Clinical Assessment needs to live up to its promise

entertainment

Will Ozempic

NIH confirmation hearing shows politicization of research

2023 STAT Wunderkinds: get to know the winners

A new House health package & hospitals’ new site

Will Ozempic

The (many) problems with a new study criticizing cancer screening

leisure time

leisure time

entertainment

hotspot